Pharmaceutical compositions comprising CB1 cannabinoid...

Details Pharmaceutical compositions comprising CB1 cannabinoid... Pharmaceutical compositions comprising CB1 cannabinoid...

2005-10-25

2011-11-15

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Acyclic nitrogen double bonded to acyclic nitrogen, acyclic...

C514S222800

Reexamination Certificate

active

08058264

ABSTRACT:
Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one KATPchannel opener as a first active agent and at least one CB1cannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined KATPchannel opening and CB1antagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising KATPchannel openers and CB1antagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset of and/or inhibition of diabetes mellitus type 1, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhbition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceutical compositions comprising a dually acting compound with combined KATPchannel opening and CB1antagonistic properties.

REFERENCES:
patent: 4070365 (1978-01-01), Van Daalen et al.
patent: 4156007 (1979-05-01), Van Daalen et al.
patent: 4174393 (1979-11-01), Van Daalen et al.
patent: 4358602 (1982-11-01), Umezawa et al.
patent: 4598089 (1986-07-01), Hadvary et al.
patent: 6267952 (2001-07-01), Mandeville, III et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 6352692 (2002-03-01), Mandeville, III et al.
patent: 6352949 (2002-03-01), Willems et al.
patent: 6476060 (2002-11-01), Lange et al.
patent: 6558657 (2003-05-01), Mandeville, III et al.
patent: 6572850 (2003-06-01), Mandeville, III et al.
patent: 6624161 (2003-09-01), Hodson et al.
patent: 6900233 (2005-05-01), Schoenafinger et al.
patent: 7037944 (2006-05-01), Piot-Grosjean et al.
patent: 7148258 (2006-12-01), Piot-Grosjean et al.
patent: 2002/0091114 (2002-07-01), Piot-Grosjean et al.
patent: 2003/0114495 (2003-06-01), Finke et al.
patent: 2003/0181433 (2003-09-01), Schoenafinger et al.
patent: 2003/0236288 (2003-12-01), Schoenafinger et al.
patent: 2004/0106800 (2004-06-01), Lange et al.
patent: 2004/0235854 (2004-11-01), Kruse et al.
patent: 2004/0248944 (2004-12-01), Kruse et al.
patent: 2005/0054679 (2005-03-01), Kruse et al.
patent: 2005/0080125 (2005-04-01), Antel et al.
patent: 2006/0258709 (2006-11-01), Piot-Grosjean et al.
patent: 2008/0058381 (2008-03-01), Piot-Grosjean et al.
patent: 25 29 689 (1976-01-01), None
patent: 31 09 335 (1982-03-01), None
patent: 0 021 506 (1981-01-01), None
patent: 0 129 748 (1985-01-01), None
patent: 0 138 280 (1985-04-01), None
patent: 0 377 457 (1990-07-01), None
patent: 2 814 678 (2002-04-01), None
patent: WO 96/03388 (1996-02-01), None
patent: WO 96/03392 (1996-02-01), None
patent: WO 99/34786 (1999-07-01), None
patent: WO 00/40247 (2000-07-01), None
patent: WO 00/40569 (2000-07-01), None
patent: WO 00/69848 (2000-11-01), None
patent: WO 01/00205 (2001-01-01), None
patent: WO 01/29007 (2001-04-01), None
patent: WO 01/70700 (2001-09-01), None
patent: WO 02/28346 (2002-04-01), None
patent: WO 02/076949 (2002-10-01), None
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/026647 (2003-04-01), None
patent: WO 03/026648 (2003-04-01), None
patent: WO 03/027076 (2003-04-01), None
patent: WO 03/039451 (2003-05-01), None
patent: WO 03/040107 (2003-05-01), None
patent: WO 03/043619 (2003-05-01), None
patent: WO 03/051851 (2003-06-01), None
patent: WO 03/063781 (2003-08-01), None
patent: WO 03/064423 (2003-08-01), None
patent: WO 03/072098 (2003-09-01), None
patent: WO 03/072555 (2003-09-01), None
patent: WO 2004/012727 (2004-02-01), None
patent: WO 2004/026301 (2004-04-01), None
patent: WO 2004/058255 (2004-07-01), None
Couper et al. Recent advances in therapy of diabetes. MJA vol. 179, Oct. 2003, pp. 441-447.
Younis et al. The prevention of type 2 diabetes mellitus: recent advances. Q J Med 2004; 97: 451-455.
Hansen et al. Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Current Medicinal Chemistry, 2004, 11, 1595-1615.
Couper et al. Recent advances in therapy of diabetes. MJA 2003; 179: 441-447.
Robertson et al. “Update on diabetes diagnosis and management” JADA, vol. 134, Oct. 2003.
A. Edgar, et al., “Photostimulated luminescence in a rare earth-doped fluorobromozirconate glass ceramic” Applied Physics Letters,(1999) vol. 75; No. 16 pp. 2386-2388.
S. Schweizer, “Physic and Current Understanding of X-Ray Storage Phosphors” Phys. Stat. Sol. (a)(2001) vol. 187; No. 2, pp. 335-393.
Gang Chen, et al., “ZBLAN-based X-ray storage phosphors and scintillators for digital X-ray imaging” Medical Imaging (2005)Proc. of SPIE vol. 5745 pp. 1351-1358.
Stefan Schweizer, et al., “Photostimulated Luminescence in Eu-doped Fluorochlorozirconate glass ceramics” Applied Physic Letters, (2003) vol. 83, No. 3 pp. 449-451.
Stefan Schweizer, et al., “Photostimulated luminescence from fluorochlorozirconate glass ceramics and the effect of crystallite size” J. of Applied Physics(2005) 97.083522.
Yoshihiro Izumi, et al., “Solid-State X-Ray Imagers” MRS Bulletin (2002) pp. 889-893.
K.H. Abel, et al., “Scintillating Glass Fiber Neutron Sensors: I Production and Optical Characterization” PNL-SA-23095.
Akaji et al., “Efficient Coupling of α, α-Dimethyl Amino Acid Using a New Chloro Imidazolidium Reagent, CIP,” Tet. Lett., 35:3315-3318 (1984).
Albericio et al., “On the Use of PyAOP, a Phosphonium Salt Derived from HOAt, in Solid-Phase Peptide Synthesis,” Tet. Lett., 38:4853-4856 (1997).
Arslanian, S., “Type 2 Diabetes in Children: Clinical Aspects and Risk Factors,” Horm. Res., 57 Suppl. 1:19-28 (2002).
Barth, F., “Cannabinoid Receptor Agonists and Antagonists,” Exp. Opin. Ther Patents, 1998, 8(3), 301-313.
Beers et al., The Merck Manual of Diagnosis and Therapy, Section 19—Pediatrics, pp. 2254-2258 (17th Ed. 1999).
Bodanszky et al., “The Practice of Peptide Synthesis,” Springer-Vertag, New York, 2nd ed., 1994.
Clerin et al., “Heterocyclisation des α-acylaminoamides. III. Proprietes des amino-5 Oxazoles,” Bull. Soc. Chim. F., 1-2:211-217 (1974).
Consroe, Paul, “Brain Cannabinoid Systems as Targets for the Therapy of Neurological Disorders.” Neurobiology of Diseases, 1998, 5:534-551, 1998.
Copending U.S. Appl. No. 10/929,377, filed Aug. 31, 2004.
Copending U.S. Appl. No. 10/933,487, filed Sep. 3, 2004.
Copending U.S. Appl. No. 10/969,840, filed Oct. 22, 2004.
Copending U.S. Appl. No. 11/005,486, filed Dec. 7, 2004.
Czollner et al., “Synthesis of New 1,5-Dipheny1-3-1H-1,2,4-triazoles Substituted with H-, Alkyl, or Carboxyl Groups at C-3,” Arch. Pharm. (Weinheim), 323:225-227 (1990).
Deckelbaum et al., “Childhood Obesity: The Health Issue,” 2001; Obesity Research; 9(Suppl. 4): 239S-243S.
Derwent Abstract for DE 25 29 689, dated Jan. 29, 1976.
Di Marzo et al., “Leptin-regulated endocannabinoids are involved in maintaining food intake,” Nature, vol. 410, pp. 822-825, 2001.
Di Marzo et al., “A Structure/Activity Relationship Study on Arvanil, an Endocannabinoid and Vinilloid Hybrid,” The Journal of Pharmacology and Experimental Therapeutics, 2002, pp. 984-991, vol. 300, No. 3.
Directive 2001/20/EC of the European Parliament and of the Counsel of Apr. 4, 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities, May 1, 2001, pp. L121/34-L121/44.
Dove, A., “Biotech Weighs Up the Options in Ob

Affiliated with

Also associated with

Rating

Pharmaceutical compositions comprising CB1 cannabinoid... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions comprising CB1 cannabinoid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising CB1 cannabinoid... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4283886